Introduction: Medication errors (MEs) are preventable incidents that can result in harm to patients. Therefore, it is essential for healthcare professionals (HCPs) to be well-informed about MEs. This study aims to assess the awareness levels of HCPs and the impact of educational intervention on their understanding of MEs. Methods: Responses to a 17-question structured, self-administered questionnaire assessing the awareness of HCPs regarding fundamental aspects of MEs, ME reporting systems, and their ability to make recommendations for improving the system for handling the MEs were collected both before and after two weeks of educational intervention administration. Results: Of a total of 114 HCPs who initially participated in the study, six dropped following the intervention. The awareness regarding the Class A questionnaire was good in most physicians (60%), nurses (60%), and pharmacists (57%) before the intervention, which improved postintervention, with physicians (80%), nurses (32%), and pharmacists (78%) demonstrating excellent awareness. The awareness level in the Class B questionnaire was also improved to excellent in most physicians (70%), pharmacists (85%), and nurses (85%) following the intervention, while it was excellent only in 50%, 35%, and 1% of physicians, pharmacists, and nurses, respectively, preintervention. In the Class C questionnaire, most physicians (40%) and nurses (60%) had good awareness, while pharmacists (35%) demonstrated excellent awareness preintervention. Postintervention, most physicians (70%), nurses (77%), and pharmacists (64%) exhibited excellent awareness. Conclusion: Most oncology practice HCPs demonstrate a good to average level of awareness regarding MEs. Clinical pharmacists’ educational interventions can significantly enhance awareness among HCPs concerning MEs.

The increased utilization of opioids in low– and middle-income countries (LMICs) presents a growing threat of opioid-related abuse, misuse and diversion. Pharmacists, as integral members of healthcare teams, are responsible for dispensing and monitoring opioid use and hold a pivotal role in opioid stewardship within LMICs. This commentary describes the potential and multifaceted roles of pharmacists in opioid stewardship in resource-constrained settings and highlights appropriate strategies for promoting responsible opioid utilization.

The role of clinical pharmacists or oncology pharmacists in pediatric oncology has been established as important in anticancer regimen review, dose calculation, recommendation, chemocounseling, identification of drug-related problems, its resolution, and, prevention and monitoring of adverse drug reactions within high-income countries. With several hospitals providing pediatric oncology services in Nepal, clinical pharmacist involvement in these hospitals is very poor. Upon reviewing the reputed organization and association focused on pediatric oncology pharmacy practice, it looks imperative for Nepal to initiate clinical pharmacy services which will further help in improving patient health outcomes. As such in this commentary, we try to accentuate the pediatric oncology services and pediatric pharmacy practice within Nepal and try to pinpoint the potential areas for clinical pharmacists to focus if they intend to provide services in pediatric oncology pharmacy practice.

Nepal, a low-middle-income country, is relatively new to clinical pharmacy. Although the program started in 2000 with several universities running it as of today, the effectiveness of this program has been under discussion since its inception regarding its syllabus, practical issues, clinical postings, and importance in hospital settings. In this commentary, we share our 14 days of experience of a clinical clerkship period carried out under a curriculum of a university constituent school in an oncology-based hospital with a clinical pharmacy department providing clinical pharmacy services.

Background: Several diseases co-exist with diabetes such as hypertension, and dyslipidemia, leading to cases of non-adherence, several drug interactions, and an increased risk of adverse drug reactions among patients, which are often termed as drug-related problems (DRPs). The role of pharmacists in high-income countries is well-defined in identifying DRPs among type 2 diabetes patients. However, these roles still need to be explored within low- and middle-income countries. The study aimed to identify DRPs in Type 2 diabetic patients. Methods: A community-based cross-sectional study was conducted in the Sunwal Municipality, Lumbini Province, Nepal from April to November 2021 where a stratified random sampling technique was employed to collect the data. The study included patients aged ≥ 18 years of either gender with type 2 diabetes who were prescribed at least one anti-diabetic medication. Patients were visited at their homes once identified through the community pharmacies, and a prescription review was conducted to identify the DRPs by using the Pharmaceutical Care Network Europe (PCNE) V8.02 tool and pertinent guidelines. Results: Among 182 patients, 97 (53.3%) had DRPs. Most of the patients were 50–60 years (n = 46; 25.3%), with a mean ± SD age of 55.43±14.46, as most were female (n = 94; 51.6%). Biguanides and sulfonylureas were the common classes of drugs prescribed. The major class of drug associated with DRPs were biguanides (n = 85; 49.7%), followed by sulfonylureas (n = 42; 24.6%). Metformin was the major drug associated with DRPs (n = 85; 49.4%). The major type of DRP identified was treatment effectiveness (n = 82; 79.61%), while patients not adhering to drug therapy (n = 97; 71.85%) was the leading cause of DRPs. DRPs were significantly associated with the duration of diabetes (p = .007) and the number of fruit servings (p = .007). Conclusion: The majority of the patients were found to have DRPs. The visiting patients at home by the pharmacists helped in identifying the DRPs and associated factors among type 2 diabetes patients, which may aid in the prevention and management of the disease.